Related coverage linked through entity extraction aliases.
May 11, 2026
Research found women undergoing breast reconstruction after mastectomy have goals extending beyond physical restoration. Newer nerve-preserving techniques aim to restore chest and nipple sensation but are still being studied.
Feb 19, 2026
Zenyaku Kogyo obtained Japanese regulatory approval for Rituxan (rituximab) as a treatment for autoimmune hemolytic anemia, a government-designated intractable disease. The approval follows a public knowledge-based application submitted in August 2025.
Feb 20, 2026
The FDA has approved the combination of Venclexta (venetoclax) plus acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated adults with chronic lymphocytic leukemia, based on Phase III AMPLIFY study results.
Feb 16, 2026
Scientists at UC San Diego have identified N4BP2 as the enzyme responsible for chromothripsis, a chaotic chromosome-shattering event seen in about one in four cancers that enables rapid tumor evolution and treatment resistance.
Feb 17, 2026
FLASH radiotherapy delivers therapeutic radiation doses in fractions of a second at rates exceeding 40 Gy per second, potentially reducing normal tissue damage while maintaining tumor control through altered oxygen dynamics.
Feb 25, 2025
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
